linjc16/ctgov huggingface dataset:
The Incidence,Factors,and Importance of Brown Adipose Tissue in Chinese Adults

Study Overview
=================
Brief Summary
-----------------
Previous studies have shown that active brown adipose tissue (BAT) is present in adults and may play important roles in material and energy metabolism. However, most of these studies were tumor-based populations and retrospective study. Due to the large amount in our cohort, the investigators are able to promote a cross-sectional study of the incidence and factors of BAT in adult chinese. In addition, the investigators can analyse the metabolic profiles in healthy adults with active BAT.

Detailed Description
-----------------
The investigators will perform a cross sectional analysis on the chinese adults who use 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) to scan the whole body at Huashan Hospital from 2009 to 2013. BAT activity will be measured by PET/CT. Not only demographic data on sex, age, medication and medical history,but also data on body composition and physical examination will be collected for all subjects. Imaging date,outdoor temperature and fasting blood samples will be collected as well. In addition, the investigators will analyse the metabolic profiles in healthy adults with active BAT and their negative controls,such as lipid profiles,fasting glucose and insulin sensitivity, adipokines and other biochemical markers.

Official Title
-----------------
Cross-sectional Study on the Incidence,Factors,and Importance of Brown Adipose Tissue in Adult Chinese

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with detectable brown adipose tissue Negative controls,consisting of one subject who underwent PET/CT scans at the same day but without detectable BAT Exclusion Criteria: Younger than 18 years Pregnant women With implantable medical electronic instrument

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brown Adipose Tissue, Cross sectional study, Chinese Adults, Factor
Inhaled Furosemide for Transient Tachypnea of Newborn

Study Overview
=================
Brief Summary
-----------------
This is a randomized double blind clinical trial in which newborns with suspected Transient tachypnea of the newborn (TTN) will receive either furosemide or normal saline by nebulizer every 6 hours for 24 hours.

Official Title
-----------------
Inhaled Furosemide for Transient Tachypnea of Newborn

Conditions
-----------------
Respiratory Morbidity

Intervention / Treatment
-----------------
* Other: Furosemide
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neonates with 34+0-39+0 gestational age on the first day of life with the clinical diagnosis of Transient Tachypnoea need for CPAP >6 hours to obtain the oxygen saturation >92% Exclusion Criteria: Systemic infection Intubation and mechanical ventilation before Inclusion in the trail Malformation and any other disease with disturb of respiratory system

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 1 Day

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Furosemide<br>Patients will receive nebulised furosemide | Other: Furosemide<br>* Patients will receive nebulised furosemide solution 1 mg/kg<br>|
| Placebo Comparator: Placebo<br>Patients will receive nebulised 0.9% saline | Other: Placebo<br>* Patients will receive nebulised 0.9% saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients with respiratory morbidity | Neonatal respiratory morbidity will be assessed through oxygen saturation, respiratory rate and duration on Continuous positive airway pressure (CPAP) | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of hospital stay | Duration of hospital stay in days | 15 days |
Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine whether an Internet based compliance tool is superior to common diet counselling in patients with hypercholesterolemia.

Official Title
-----------------
Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement of LDL Goals. - Denmark

Conditions
-----------------
Hypercholesterolemia

Intervention / Treatment
-----------------
* Procedure: Lifestyle Regulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Available personal mailbox and access to the Internet Primary hypercholesterolemia with CV risk > 20% over 10 years judged by the investigator or a history of ischemic heart disease or other established atherosclerotic disease (claudicatio intermittens, apoplexia cerebri (ischaemic stroke)) or stable diabetes mellitus Fasting LDL-C level > 3.2 mmol/L Exclusion Criteria: Known heterozygous or homozygous familial hypercholesterolemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia) Documented secondary hypercholesterolemia of any cause except stable diabetes mellitus (type 1 or type 2) History of serious adverse effect or hypersensitivity reactions to statins, in particular any history of myopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Lifestyle Regulation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint is the number and percentage of subjects from each group (rosuvastatin or rosuvastatin + a compliance enhancement tool) who reached the DSAM LDL-C target goal (LDL-C < 3.0 mmol/L) after 6 months therapy (24 weeks). |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number and percentage of subjects within the DSAM LDL-C target goal after 3 months therapy |  |  | 
| Compliance with study drug assessed by tablet count data |  |  | 
| Number and percentage of subjects increasing rosuvastatin dosage from 10 mg to 20 mg at week 12 |  |  | 
| Percentage change in TC, HDL-C, LDL-C, TG from week 0 to week 24 |  |  | 
| Change in weight after 6 months therapy |  |  | 
| Change in waistline after 6 months therapy |  |  |
Assessment of Teleconsulting in Nursing Homes to Avoid Transportations to the Emergency Units

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether teleconsulting would be effective and cost-effective by reducing the patients transportations and the use of emergency units for nursing home residents.

Official Title
-----------------
Assessment of Teleconsulting in Nursing Homes to Avoid Transportations to the Emergency Units

Conditions
-----------------
Nursing Homes Residents

Intervention / Treatment
-----------------
* Device: Residents of nursing homes with telemedicine after implementation of telemedicine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All residents of selected nursing homes Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group before telemedicine<br>Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine | |
| Control group after telemedicine<br>Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine | |
| Exposed group, before telemedicine<br>Residents of nursing homes with telemedicine prior implementation of telemedicine | |
| Exposed group, after telemedicine<br>Residents of nursing homes with telemedicine after implementation of telemedicine | Device: Residents of nursing homes with telemedicine after implementation of telemedicine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of hospital stay |  | Within 1 year after start of the study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient transportation to a emergency unit |  | Within 1 year after start of the study | 
| Number of hospitalizations |  | Within 1 year after start of the study | 
| Global costs |  | Within 1 year after start of the study |
SOURCE 3: Observational Study to Evaluate Safety and Performance of SAPIEN 3 THV System in Real Life Practice

Study Overview
=================
Brief Summary
-----------------
This is an international, mutli-center, prospective, consecutively enrolled, observational registry. 2000 patients are planned to be enrolled over one year at up to 150 participating sites. 300 patients out of the 2000 patients enrolled in the main registry are planned to be consecutively enrolled in a select few sites for studying the valve performance. Echocardiogram and angiogram will be taken routinely.

Detailed Description
-----------------
The purpose of this registry is to provide clinical outcome and safety information on patients that will be treated with the Edwards SAPIEN 3 Transcatheter Heart Valve and delivery devices for severe, symptomatic calcific aortic stenosis. In addition, the information collected will serve post market safety and surveillance regulatory obligations. Consecutive patient data will be collected at baseline, procedure, discharge, after discharge (at approx. 30 days post-index procedure), 12 months post-index procedure and annually thereafter up to 5 years post-implant according to usual practice at site.

Official Title
-----------------
Edwards SAPIEN 3 Aortic Bioprosthesis Multi-Region Outcome Registry

Conditions
-----------------
Aortic Stenosis

Intervention / Treatment
-----------------
* Device: TAVI (Transcatheter Aortic Valve Implantation)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient suffering from severe, symptomatic, calcific aortic stenosis STS Score ≥ 8 Logistic EuroSCORE ≥15 Exclusion Criteria: Congenital unicuspid or congenital bicuspid aortic valve Evidence of intracardiac mass, thrombus or vegetation Active infection or endocarditis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: TAVI (Transcatheter Aortic Valve Implantation)|Edwards SAPIEN 3 Transcatheter Heart Valve (S3 THV) and Edwards Commander Delivery system (transfemoral) and Certitude Delivery system (transapical/transaortic). The Edwards S3 THV is indicated for use in patients with severe, symptomatic, calcific aortic stenosis with STS Score ≥ 8 or Logistic EuroSCORE ≥15|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SAPIEN 3 THV, TAVI, Transfemoral, Transaortic, Transapical, Aortic valve
Efficacy of Ethnodyne Visio in Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
ETHNODYNE VISIO is a food supplement composed of an innovative plant-based active ingredient acting alongside vitamin B2. It is proposed in patients with visual problems. Based on clinical and experimental data, the investigators propose a pilot open study in order to test the efficacy of Ethnodyne visio in patients with Parkinson 's disease (PD). The hypothesis is that Ethnodyne visio may improve motor and non motor signs of PD. 24 patients with PD will be evaluated before and after 3 months of add on treatment by Ethnodyne visio.

Conditions
-----------------
Parkinson's Disease

Intervention / Treatment
-----------------
* Dietary Supplement: ETHNODYNE VISIO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Parkinson disease (PD) with at least 3 years of evolution Hoehn and Yahr score 2 or 3 with moderate fluctuations (score 1 or 2 for item 3 score IV MSD UPDRS) with no modification in anti-parkinsonian drugs since at least 1 month minimental test >24 Exclusion Criteria: known intolerance to Ethnodyne visio woman of childbearing potential or breastfeeding anticipated anti-parkinsonian treatment modification during the 3 months of the study antidepressant or anxiolytic drugs modified within one month prior to inclusion visit other chronic disease concomitant participation in a another clinical trial Subject under legal guardianship

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ETHNODYNE VISIO<br>Administration 2 times a day of a dietary supplement, as add on therapy, in patients with Parkinson s disease | Dietary Supplement: ETHNODYNE VISIO<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in MDS UPDRS III score |  | baseline and following 3 months of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in MDS UPDRS I, II and IV score |  | baseline and following 3 months of treatment | 
| Change in Levodopa equivalent dose treatment (equivalence table) |  | baseline and following 3 months of treatment | 
| Frequency, seriousness and severity of adverse event reactions |  | during the 3 months of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Treatment, Motor signs, Non motor signs, Fluctuations, Open labelled
Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if pretreatment with Estrogen can assist in the planning and programming of In Vitro Fertilization treatments.

Detailed Description
-----------------
A randomised controlled trial in which study group will be given estrogen derivative before ovarian stimulation in GnRH antagonist protocol and compared to the classical GnRH agonist protocol.Estrogen will be given P.O , PROGYNOVA' , in a dose of 2 mg /d, starting day 2 of menses and until first Monday to follow. Main outcome measure will be ability to control the ovum pickup day, calculated as a rate of ideal pickups divided by the entire pickup number. All women enrolled will be under 38 years of age, with a clear indication for IVF other than ovulatory dysfunction. women with past 4 treatment failures will be excluded as well as cases in which sperm achieved in surgical methods.

Official Title
-----------------
Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Drug: estradiol valerate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IVF treatment in the following indications: Male, Mechanical, Unexplained Age<38 years Treatment Cycle number 1-4 Exclusion Criteria: Ovulatory disorder as an indication for IVF Repeated failure in previous IVF treatments (> than 4 cycles) Sperm used for treatment was retrieved by surgical procedure

Ages Eligible for Study
-----------------
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Follicular Estrogen, Antagonist, IVF<br>Follicular Estrogen in Antagonist IVF protocol | Drug: estradiol valerate<br>* 2 mg P.O / day for 1-6 days.<br>|
| Active Comparator: long IVF protocol<br>long IVF protocol | Drug: estradiol valerate<br>* 2 mg P.O / day for 1-6 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ovum pickup rate that took place between Sunday to Thursday without a compromise | number of Pickups that took place between Sunday to Thursday (without a compromise in treatment) \ by the entire pickup number | a year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pregnancy rate | comparison of pregnancy rate between the 2 groups. calculated per cycle | a year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infertility, IVF, Estrogen
Qualitative Descriptive Study of the Meaning of the Ward Round

Study Overview
=================
Brief Summary
-----------------
A qualitative descriptive design. A phenomenologic approach to investigate the meaning of the ward round. Interviews of patients, nurses and physicians. A Master thesis.

Official Title
-----------------
Qualitative Descriptive Study of the Meaning of the Ward Round

Conditions
-----------------
Teaching Rounds

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Grown-ups, normal cognitive function, speaks norwegian. Exclusion Criteria: Children, vulnerable patientgroups, students.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Heterogeneous groups of patients (age, gender) | |
| Nurses<br>Heterogeneous groups of nurses (age, gender, working experience) | |
| Physicians<br>Heterogeneous groups of physicians (age, gender, working experience) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Qualitative Research, Interview, Psychological, Patients, Nurses, Physicians
Deployment-Related Lung Disease Research Database and Biorepository

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to establish a research database and biorepository for patients at National Jewish Health (NJH) who served in Operation Iraqi Freedom (OIF) or Operation Enduring Freedom (OEF). This study will also include civilian contractors who worked as part of these military operations in Iraq or Afghanistan. The biorepository would store blood samples obtained from these patients during a clinic visit. The research database would store prospectively and retrospectively collected clinical and exposure data that would enable us to comprehensively characterize each case.

Detailed Description
-----------------
If informed consent is obtained, test results and other information collected for clinical reasons will be entered in a research database designed and maintained by DEOHS staff. The clinical data collected are part of the routine diagnosis and care of these patients. No additional procedures are required for the purpose of this research database. Collection of symptom and exposure data using a questionnaire designed for this study. All NJH patients who served in southwest Asia will be approached for inclusion in the study. This will also attempt to contact patients evaluated previously at NJH for deployment-related lung disease to obtain informed consent to include data from their medical record and the research questionnaire in the database.

Official Title
-----------------
Deployment-Related Lung Disease Research Database and Biorepository

Conditions
-----------------
Bronchiolitis

Intervention / Treatment
-----------------
* Other: Biorepository


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Served in the southwest Asia wars Exclusion Criteria: Did not served in the southwest Asia wars

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Biorepository|One-time blood draw for blood to be stored in a biorepositoy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| collect symptom and exposure data | each subject will complete a questionnaire | Up to 24 months |